Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Podcasts|December 1, 2009
Challenges in the Treatment of Patients With Bipolar Depression
Charles Bowden, MD, clinical professor in the department of psychiatry at the University of Texas Health Science Center, San Antonio, describes the challenges physicians face when they treat patients with bipolar depression.
Advertisement
Charles Bowden, MD, clinical professor in the department of psychiatry at the University of Texas Health Science Center, San Antonio, describes the challenges physicians face when they treat patients with bipolar depression. This is the second podcast interview in a series on the diagnosis and treatment of patients with bipolar depression.
Challenges in the Treatment of Patients With Bipolar Depression
Advertisement
Related to this article
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5